WO2004098494A3 - Compounds, compositions, and methods - Google Patents

Compounds, compositions, and methods Download PDF

Info

Publication number
WO2004098494A3
WO2004098494A3 PCT/US2004/011267 US2004011267W WO2004098494A3 WO 2004098494 A3 WO2004098494 A3 WO 2004098494A3 US 2004011267 W US2004011267 W US 2004011267W WO 2004098494 A3 WO2004098494 A3 WO 2004098494A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
compounds
methods
fungal
kip1
Prior art date
Application number
PCT/US2004/011267
Other languages
French (fr)
Other versions
WO2004098494A2 (en
Inventor
Adam Tomasi
Bradley P Morgan
Jr David J Morgans
Andrew Mcdonald
David Roof
Mary Maxon
Original Assignee
Cytokinetics Inc
Adam Tomasi
Bradley P Morgan
Jr David J Morgans
Andrew Mcdonald
David Roof
Mary Maxon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc, Adam Tomasi, Bradley P Morgan, Jr David J Morgans, Andrew Mcdonald, David Roof, Mary Maxon filed Critical Cytokinetics Inc
Priority to EP04750041A priority Critical patent/EP1620413A2/en
Publication of WO2004098494A2 publication Critical patent/WO2004098494A2/en
Publication of WO2004098494A3 publication Critical patent/WO2004098494A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Abstract

Substituted indoles useful for treating fungal infections by modulating the activity of the fungal kinesin Kip1 are disclosed.
PCT/US2004/011267 2003-04-30 2004-04-29 Compounds, compositions, and methods WO2004098494A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04750041A EP1620413A2 (en) 2003-04-30 2004-04-29 Compounds, compositions, and methods

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46697303P 2003-04-30 2003-04-30
US46716503P 2003-04-30 2003-04-30
US60/467,165 2003-04-30
US60/466,973 2003-04-30

Publications (2)

Publication Number Publication Date
WO2004098494A2 WO2004098494A2 (en) 2004-11-18
WO2004098494A3 true WO2004098494A3 (en) 2005-03-24

Family

ID=33436714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011267 WO2004098494A2 (en) 2003-04-30 2004-04-29 Compounds, compositions, and methods

Country Status (2)

Country Link
EP (1) EP1620413A2 (en)
WO (1) WO2004098494A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1988397E (en) 2002-12-19 2011-12-02 Scripps Research Inst Compositions and uses for stabilising transthyretin and inhibiting transthyretin misfolding
TW200517381A (en) 2003-08-01 2005-06-01 Genelabs Tech Inc Bicyclic heteroaryl derivatives
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
MXPA06013381A (en) 2004-05-20 2007-03-01 Scripps Research Inst Transthyretin stabilization.
WO2006110683A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7906522B2 (en) 2005-04-28 2011-03-15 Kyowa Hakko Kirin Co., Ltd 2-aminoquinazoline derivatives
MX2007015689A (en) * 2005-06-21 2008-02-21 Neurosearch As 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels.
US7737166B2 (en) 2005-08-17 2010-06-15 Daiichi Sankyo Company, Limited Antifungal bicyclic hetero ring compounds
JP5162465B2 (en) 2005-11-15 2013-03-13 アボット・ラボラトリーズ Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
SI1986633T1 (en) 2006-02-10 2015-03-31 Summit Corporation Plc Treatment of duchenne muscular dystrophy
ATE553104T1 (en) 2006-05-02 2012-04-15 Abbott Lab SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDE AS POTENT PARP INHIBITORS
PE20080888A1 (en) 2006-10-18 2008-08-26 Novartis Ag HETEROCYCLIC COMPOUNDS AS ACIL-TRANSFERASE INHIBITORS OF ACIL-CoA-DIACIL-GLYCEROL 1 (DGAT1)
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
WO2009017822A2 (en) * 2007-08-02 2009-02-05 Amgen Inc. Pi3 kinase modulators and methods of use
PL2170396T3 (en) 2007-08-03 2017-07-31 Summit (Oxford) Limited Drug combinations for the treatment of duchenne muscular dystrophy
PE20091268A1 (en) * 2007-12-19 2009-09-19 Amgen Inc HETEROCYCLIC DERIVATIVES AS PI3 KINASE INHIBITORS
JP2011511078A (en) 2008-02-06 2011-04-07 レアド トヘラペウトイクス，インコーポレーテッド Benzoxazole carboxamide inhibitors of poly (ADP ribose) polymerase (PARP)
US20110039845A1 (en) 2008-04-23 2011-02-17 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
KR101257158B1 (en) 2008-05-23 2013-04-23 노파르티스 아게 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
TW201000099A (en) 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
WO2010133534A1 (en) * 2009-05-19 2010-11-25 Cellzome Limited Bicyclic amino substituted compounds as pi3k inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
MX337662B (en) 2010-10-06 2016-03-14 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors.
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
RU2586330C2 (en) 2011-09-16 2016-06-10 Пфайзер Инк. Solid forms of transthyretin dissociation inhibitor
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
TWI530499B (en) 2013-03-28 2016-04-21 吉李德科學股份有限公司 Benzimidazolone derivatives as bromodomain inhibitors
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
TWI527811B (en) 2013-05-09 2016-04-01 吉李德科學股份有限公司 Benzimidazole derivatives as bromodomain inhibitors
SG11201510409QA (en) 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
EP3010917B1 (en) 2013-06-21 2018-01-31 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
JP6542212B2 (en) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． Novel quinazolinones as bromodomain inhibitors
US9108953B2 (en) 2013-11-26 2015-08-18 Gilead Sciences, Inc. Quinoline derivatives as bromodomain inhibitors
JO3512B1 (en) 2014-03-26 2020-07-05 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
MA55696A (en) 2014-03-26 2022-02-23 Astex Therapeutics Ltd COMBINATIONS
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
JP2017538721A (en) 2014-12-17 2017-12-28 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． Bromodomain inhibitors
JOP20200201A1 (en) 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
DK3353177T3 (en) 2015-09-23 2020-08-24 Janssen Pharmaceutica Nv TRICYCLIC HETEROCYCLES FOR CANCER TREATMENT
HRP20220012T1 (en) 2015-09-23 2022-04-01 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
WO2023283425A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795903A (en) * 1994-10-26 1998-08-18 Rhone-Poulenc Rorer S.A. 6-polyfluoroalkoxy-and 6-polyfluoroalkyl-2-aminobenzothiazole derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795903A (en) * 1994-10-26 1998-08-18 Rhone-Poulenc Rorer S.A. 6-polyfluoroalkoxy-and 6-polyfluoroalkyl-2-aminobenzothiazole derivatives

Also Published As

Publication number Publication date
EP1620413A2 (en) 2006-02-01
WO2004098494A2 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
WO2004098494A3 (en) Compounds, compositions, and methods
WO2004018058A3 (en) Compounds, compositions, and methods
WO2006113432A3 (en) Compounds, compositions and methods
WO2006015159A3 (en) Potassium channel inhibitors
WO2004103960A3 (en) Compounds and uses thereof
WO2005030791A3 (en) Isoquinolinone potassium channel inhibitors
WO2006060535A3 (en) Indole derivatives for use as ppar active compounds
WO2006060456A3 (en) Indole derivatives for use as ppar ppar active compounds
WO2008051197A3 (en) Small-molecule botulinum toxin inhibitors
WO2003094839A8 (en) Pyrimidinone compounds, compositions and methods
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2003088903A3 (en) Compounds, compositions, and methods
WO2005012243A3 (en) Substituted indole-o-glucosides
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2005042497A3 (en) Benzimidazoles useful as modulators of ion channels
WO2005046578A3 (en) Isoquinolinone potassium channel inhibitors
WO2004009036A3 (en) Compounds compositions and methods
WO2005030130A3 (en) Isoquinoline potassium channel inhibitors
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
WO2005117543A3 (en) N-sulfonylcarboximidamide apoptosis promoters
WO2004006865A3 (en) Compounds, compositions, and methods
EP1667685A4 (en) Quinazoline potassium channel inhibitors
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors
WO2005033112A3 (en) Substituted indole derivatives
WO2004032840A3 (en) Compounds, compositions, and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004750041

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004750041

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004750041

Country of ref document: EP